Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.
The sequelae of treatment modalities used to treat childhood cancer are of increasing clinical importance. In children with pediatric malignancies, the full impact of such sequelae may not be apparent until years after treatment. The earlier recognition of these neurotoxicities could possibly alter the course of a treatment or facilitate interventions to improve quality of life.
De Braganca
Kevin C
KC
Division of Neurology, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA. kdebraga@cnmc.org
Packer
Roger J
RJ
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D016207:Cytokines / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D013995:Time
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016207:Cytokines